TABLE 1.
Sociodemographic, virologic, serologic, and drug use characteristics of members of the study groupa
| Determinant | Value for:
|
|
|---|---|---|
| Case subjects (n = 5) | Control subjects (n = 10) | |
| Ageb | 27 (25–33) | 30 (23–50) |
| Male (%) | 80 | 80 |
| African-American (%) | 40 | 60 |
| Sampling intervalc | 3.3 (−3.3–40.9) | 3.0 (−13.9–41.4) |
| Drug used | 173 (1–917) | 377 (0–1180) |
| HIV seropositive (%) | 20 | 20 |
| Log10 [HCV RNA]e | 5.2 (3.3–7.6) | 4.8 (2.7–7.4) |
a
P > 0.05 for all comparisons. Case subjects showed clearance of viremia; control subjects showed persistence of viremia.
b
Median age at the time of HCV seroconversion in years (range).
c
Number of months from HCV seroconversion to HCV RNA detection. Negative values indicate RNA detected prior to seroconversion; median (range).
d
Self-reported drug use in episodes during the year following HCV seroconversion; median (range).
e
[HCV RNA], HCV RNA copies per milliliter of serum, at the time of sampling for this study; median (range).